Cited by 70HIV-related health complications and treatmentsTelomeres, Telomerase, and SenescenceBone Metabolism and Diseases

HIV protease inhibitors induce senescence and alter osteoblastic potential of human bone marrow mesenchymal stem cells: beneficial effect of pravastatin

Open access
Hernandez‐Vallejo, Sandra J., Beaupere, Carine, Larghero, Jerome, Capeau, Jacqueline, Lagathu, Claire·2013·Aging Cell

Abstract

Summary: HIV‐infected patients receiving antiretroviral therapy present an increased prevalence of age‐related comorbidities, including osteoporosis. HIV protease inhibitors ( PI s) have been suspected to participate to bone loss, but the mechanisms involved are unknown. In endothelial cells, some PI s have been shown to induce the accumulation of farnesylated prelamin‐ A , a biomarker of cell aging leading to cell senescence. Herein, we hypothesized that these PI s could induce premature aging of osteoblast precursors, human bone marrow mesenchymal stem cells ( MSC s), and affect their capacity to differentiate into osteoblasts. Senescence was studied in proliferating human MSC s after a 30‐day exposure to atazanavir and lopinavir with or without ritonavir. When compared to untreated cells, PI ‐treated MSC s had a reduced proliferative capacity that worsened with increasing passages. PI treatment led to increased oxidative stress and expression of senescence markers, including prelamin‐ A . Pravastatin, which blocks prelamin‐ A farnesylation, prevented PI ‐induced senescence and oxidative stress, while treatment with antioxidants partly reversed these effects. Moreover, senescent MSC s presented a decreased osteoblastic potential, which was restored by pravastatin treatment. Because age‐related bone loss is associated with increased bone marrow fat, we also evaluated the capacity of PI ‐treated MSC s to differentiate into adipocyte. We observed an altered adipocyte differentiation in PI ‐treated MSC s that was reverted by pravastatin. We have shown that some PI s alter osteoblast formation by affecting their differentiation potential in association with altered senescence in MSC s, with a beneficial effect of statin. These data corroborate the clinical observations and allow new insight into pathophysiological mechanisms of PI ‐induced bone loss in HIV ‐infected patients.

Integrity signals

Registry

Crossref · 10.1111/acel.12119

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • HIV proteins Tat and Nef and protease inhibitors lopinavir and atazanavir are capable of inducing senescence in BM-MSCs.

    “These conflicts are possibly reconciled by reports that find both HIV proteins Tat and Nef and protease inhibitors lopinavir and atazanavir are capable of inducing senescence in BM‐MSCs.”

    From The struggle of a good friend getting old: cellular senescence in viral responses and therapy (2021) · cites this paper as Hernandez‐Vallejo et al, 2013

  • Senescent BM-MSCs do not effectively differentiate into osteoblasts and deposit reduced calcium in vitro.

    “Importantly, senescent BM‐MSCs do not be effectively differentiated into osteoblasts and deposit reduced levels of calcium in vitro (Hernandez‐Vallejo et al, 2013; Beaupere et al, 2015).”

    From The struggle of a good friend getting old: cellular senescence in viral responses and therapy (2021) · cites this paper as Hernandez‐Vallejo et al, 2013

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Hernandez‐Vallejo, S. J., Beaupere, C., Larghero, J., Capeau, J., & Lagathu, C.
Affiliations
  • INSERM UMRS938 Paris France
  • Cell Therapy Unit Hôpital Saint Louis Paris France
  • Inserm (FR)
Corresponding author
Lagathu, Claire
Venue
Aging Cell
Publisher
Wiley
Published
2013-07-19
Volume
12
Issue
6
Pages
955-965
ISSN
  • 1474-9718 (ISSN-L)
  • 1474-9726
OpenAlex
W2134828479
Cited by
70
References
45
Citations by year
2026: 2 · 2025: 2 · 2024: 2 · 2022: 6 · 2021: 6 · 2020: 8 · 2019: 8 · 2018: 4 · 2017: 6 · 2016: 8 · 2015: 6 · 2014: 11 · 2013: 1
FWCI
8.55
Type
journal article
Language
en
Open access
Locations
  • Aging Cell (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Emergency Medicine › HIV-related health complications and treatments
  • Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Keywords
HIV protease inhibitors, bone marrow mesenchymal stem cells, cellular senescence, osteogenic differentiation, pravastatin, atazanavir, lopinavir, ritonavir, oxidative stress, osteoporosis, bone loss, adipogenesis, statins, HIV-associated bone loss
MeSH terms
Atazanavir Sulfate, Antioxidants, Bone Marrow Cells, Cell Differentiation, Humans, Oligopeptides, Osteoblasts, Pyridines, Cellular Senescence, Pravastatin, HIV Protease Inhibitors, Oxidative Stress, Cell Proliferation, Adipogenesis, Mesenchymal Stem Cells, Lopinavir

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review